- Home
- PMN vs ALLR Comparison
PMN vs ALLR Comparison
Compare PMN & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMN
- ALLR
- Stock Information
- Founded
- PMN 2004
- ALLR 2004
- Country
- PMN Canada
- ALLR United States
- Employees
- PMN N/A
- ALLR N/A
- Industry
- PMN Pharmaceuticals and Biotechnology
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- PMN Health Care
- ALLR Health Care
- Exchange
- PMN Nasdaq
- ALLR Nasdaq
- Market Cap
- PMN 16.0M
- ALLR 15.8M
- IPO Year
- PMN N/A
- ALLR N/A
- Fundamental
- Price
- PMN $0.62
- ALLR $0.96
- Analyst Decision
- PMN Strong Buy
- ALLR Strong Buy
- Analyst Count
- PMN 3
- ALLR 1
- Target Price
- PMN $4.33
- ALLR $9.00
- AVG Volume (30 Days)
- PMN 16.6M
- ALLR 489.1K
- Earning Date
- PMN 08-13-2025
- ALLR 08-15-2025
- Dividend Yield
- PMN N/A
- ALLR N/A
- EPS Growth
- PMN N/A
- ALLR N/A
- EPS
- PMN N/A
- ALLR N/A
- Revenue
- PMN N/A
- ALLR N/A
- Revenue This Year
- PMN N/A
- ALLR N/A
- Revenue Next Year
- PMN N/A
- ALLR N/A
- P/E Ratio
- PMN N/A
- ALLR N/A
- Revenue Growth
- PMN N/A
- ALLR N/A
- 52 Week Low
- PMN $0.38
- ALLR $0.61
- 52 Week High
- PMN $1.59
- ALLR $6.00
- Technical
- Relative Strength Index (RSI)
- PMN 47.41
- ALLR 44.95
- Support Level
- PMN $0.77
- ALLR $0.93
- Resistance Level
- PMN $0.73
- ALLR $1.01
- Average True Range (ATR)
- PMN 0.09
- ALLR 0.05
- MACD
- PMN -0.02
- ALLR -0.01
- Stochastic Oscillator
- PMN 21.39
- ALLR 14.00
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.